Results 201 to 210 of about 1,914,121 (297)

Correlations Among Glycemia and Glucose Variability, Thyroid Hormones, and Albuminuria in Patients With Type 2 Diabetes Mellitus

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hyperglycemia, glucose fluctuations, and thyroid dysfunction contribute to the progression of diabetic nephropathy. This study aimed to investigate the associations of glycemia, glucose variability, and thyroid hormones with albuminuria in patients with type 2 diabetes mellitus (T2DM). In total, 451 T2DM patients were included.
Na Luo, Shang‐Yong Feng, Hui Chen, Dun‐Min She, Yan Liu, Ying Li, Cai‐Feng Yan, Zhen‐Wen Zhang, Jing Chen, Xiao‐Li Cai, Gao‐Yu Zhao, Hui Yu, Yan Wang   +12 more
wiley   +1 more source

Thyroid hormone receptor blockade by amiodarone disrupts angiogenesis via VEGFα, WNT7A, BMP, and PI3K/AKT pathways in chick embryo vascular development. [PDF]

Dev Dyn
Vaishnav J, Balakrishnan S.
europepmc   +1 more source

Development and External Validation of a Postoperative Risk Score for Venous Thromboembolism in Epithelial Ovarian Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a major complication in women with epithelial ovarian cancer (EOC). We aimed to develop and externally validate an early postoperative risk score to identify EOC patients at increased risk of VTE after debulking surgery.
Qiu‐Lin Cui, Yu‐Shi He, Xuan‐Hui Wang, Cheng Li, Gang Wang, Ming Chen, Shu‐Min Chen   +6 more
wiley   +1 more source

Thyroid Hormone Receptor β Suppresses Cancer Cell Activity by Differential Regulation of Glycogen Metabolism.

Endocrinology
Zielinski JM, Tomczak JA, Amiel E, Carr FE.   +3 more
europepmc   +1 more source

Thyroid Hormone Resistance: A Case Report of a Novel Missense Thyroid Hormone Receptor (THR) Mutation. [PDF]

Cureus
Nahar ML, Cui L.
europepmc   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

In Silico Study of Natural Polyphenols as Potential Metabolic Modulators in Mitigating Lipotoxicity in Non-Alcoholic Fatty Liver Disease via Thyroid Hormone Receptor Alpha Activation. [PDF]

Curr Issues Mol Biol
Konstantinou EK, Panagiotopoulos AA, Dimitriou M.   +2 more
europepmc   +1 more source

Risk Factors Influencing Efficacy and Prognosis Evaluation of Neoadjuvant Systemic Therapy in Triple‐Positive Breast Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT To identify the determinants of the response to neoadjuvant systemic therapy (NST) in triple‐positive breast cancer (TPBC), we retrospectively enrolled 520 patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer who were treated at The First Affiliated Hospital of Chongqing Medical University between January 2015 ...
Lin‐Rui Miao, Hao Liu, Hai‐Ying Yu, Jian Chen, Ming‐Yu Yang, Ya‐Lan Zhang, Gang Tu, Ling‐Feng Tang   +7 more
wiley   +1 more source

DARS2 Promotes Tumorigenesis and Metastasis by Activating PI3K/Akt/GSK‐3β/β‐Catenin Signaling Pathway in Breast Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Aspartyl‐tRNA synthetase 2 (DARS2), the mitochondrial enzyme responsible for aminoacylation of aspartyl‐tRNA, is traditionally known for its effect on protein synthesis. Recently, DARS2 is reported to be implicated in tumorigenesis. However, its specific effect on breast cancer (BC) is poorly understood.
Na Wang, Ming Huang
wiley   +1 more source

Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD). [PDF]

Portal Hypertens Cirrhosis
Liu CH, Zeng QM, Hu TY, Huang Y, Song Y, Guan H, Rockey DC, Tang H, Li S.   +8 more
europepmc   +1 more source